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Background: The septin 9 gene (SEPT9) codes for a GTP-binding protein associated with filamentous structures
and cytoskeleton formation. SEPT9 plays a role in multiple cancers as either an oncogene or a tumor suppressor
gene. Regulation of SEPT9 expression is complex and not well understood; however, hypermethylation of the gene
was recently introduced as a biomarker for early detection of colorectal cancer (CRC) and has been linked to cancer
of the breast and of the head and neck. Because the DNA methylation landscape of different regions of SEPT9 is
poorly understood in cancer, we analyzed the methylation patterns of this gene in distinct cell populations from
normal and diseased colon mucosa.
Methods: Laser capture microdissection was performed to obtain homogeneous populations of epithelial and
stromal cells from normal, adenomatous, and tumorous colon mucosa. Microdissected samples were analyzed using
direct bisulfite sequencing to determine the DNA methylation status of eight regions within and near the SEPT9
gene. Septin-9 protein expression was assessed using immunohistochemistry (IHC).
Results: Regions analyzed in SEPT9 were unmethylated in normal tissue except for a methylation boundary
detected downstream of the largest CpG island. In adenoma and tumor tissues, epithelial cells displayed markedly
increased DNA methylation levels (>80%, p <0.0001) in only one of the CpG islands investigated. SEPT9 methylation
in stromal cells increased in adenomatous and tumor tissues (≤50%, p <0.0001); however, methylation did not
increase in stromal cells of normal tissue close to the tumor. IHC data indicated a significant decrease (p <0.01) in
Septin-9 protein levels in epithelial cells derived from adenoma and tumor tissues; Septin-9 protein levels in stromal
cells were low in all tissues.
Conclusions: Hypermethylation of SEPT9 in adenoma and CRC specimens is confined to one of several CpG islands
of this gene. Tumor-associated aberrant methylation originates in epithelial cells; stromal cells appear to acquire
hypermethylation subsequent to epithelial cells, possibly through field effects. The region in SEPT9 with disease-
related hypermethylation also contains the CpGs targeted by a novel blood-based screening test (Epi proColon®),
providing further support for the clinical relevance of this biomarker.
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Alterations in the DNA methylation profile of cells are
among the earliest molecular changes in cancer [1].
Both locus-specific hypermethylation and genome-wide
hypomethylation commonly occur in different types of
tumors [2]. Hypermethylation of tumor suppressor genes
has been identified as a critical step in tumor initiation as
the silenced expression of such genes affects whether cells
maintain normal growth. Such epigenetic events, along
with mutations, provide cells with a selective advantage
that may lead to their clonal expansion [3].
Septin 9 (SEPT9)a involvement in cancer was first discov-
ered as a fusion product with the MLL gene in leukemia
[4]. Subsequent studies showed that SEPT9 was frequently
deleted in sporadic ovarian tumors [5] or amplified in
breast cancer [6]; it was suggested that the gene might
be a candidate ovarian tumor suppressor gene that may
also act like an oncogene. A comprehensive screen of a
wide variety of tissue samples and cell lines revealed that
SEPT9 was ubiquitously expressed, although, its isoform
expression appeared to be tissue specific [7]. Moreover,
SEPT9 mRNA and protein were overexpressed in diverse
human tumors further suggesting an important role of
the gene in tumorigenesis.
SEPT9 belongs to a highly conserved family of septin
genes coding for GTP-binding proteins. These multidomain
proteins assemble into complexes and form filamentous
structures which comprise part of the cytoskeleton [8,9].
The septin proteins play important roles in many cellular
processes by providing rigidity to the cell membrane,
serving as scaffolds to recruit proteins to specific sub-
cellular locales, and creating membrane diffusion bar-
riers to establish discrete cellular domains [8]. SEPT9 is
characterized by its complex genomic organization that
spans 219 kb and has 18 distinct transcripts encoding
15 isoforms [10,11]. Alternative splicing at both 5′ and
3′ ends generates this transcript diversity [10]. The gene
also harbors several CpG islands that when methylated
may impact the expression of different transcripts.
Several analyses have been conducted on the expres-
sion of the SEPT9 transcripts. The transcript SEPT9_v1
was overexpressed in breast, ovarian, and prostate cancer
while no SEPT9_v1 expression was observed in the normal
tissue of these organs [12,13]. Two distinct transcripts,
SEPT_v4 and SEPT_v4*, code for the same polypeptide,
but are translated with different efficiencies and respond
differently to cellular stresses; the SEPT9_v4* polypep-
tide is thought to play a role in neoplasia [14,15]. The
transcript SEPT9_v3 expression was up-regulated in some
cancer cell lines and repressed in others in which there
was also a reduction in protein levels [16]. This transcript
was also associated with promoter hypermethylation.
Recently, SEPT9 was shown to be epigenetically modi-
fied in colorectal cancer (CRC) [17]. Subsequent studiesusing refined and more sensitive assays confirmed SEPT9
as a biomarker for CRC [18,19]. A complete workflow was
developed on the basis of these findings and permits a min-
imally invasive, blood-based screening test (Epi proColon®)
for colorectal cancer [20], which is currently available for
clinical application in Europe [21]. The test detects meth-
ylated SEPT9 in circulating DNA in plasma which is
believed to be derived from apoptotic cells shed from
the tumor [22]. However, it is unknown whether SEPT9
hypermethylation is present in all types of tumor cells
of the colon and to what extent the hypermethylation
affects the promoter region of SEPT9. To advance our
understanding of cancer-associated epigenetic changes
in SEPT9, we investigated the methylation profile of
SEPT9 in epithelial and stromal cells microdissected from
normal and diseased fresh-frozen biopsies and tissue colon
samples. Since earlier studies analyzed DNA methylation
changes only in a single SEPT9 CpG island, and only in
heterogeneous CRC tissue specimens, this study aims at
determining whether the aberrant methylation changes are
unique to only this CpG island or whether hypermethylation
affects multiple CpG dense regions associated with this gene
and how SEPT9 methylation is affected in homogeneous
populations of epithelial and stromal cells.
Our results provide new insights into the cellular origin
of aberrant DNA methylation in the SEPT9 gene for CRC
and the clinical relevance of DNA methylation for early
CRC detection.
Methods
Clinical data
Biopsies of normal mucosa were obtained from three
patients, aged 32 to 72 during routine endoscopy exami-
nations (Additional file 1: Table S1). Patients from whom
normal tissue samples were obtained were verified to be
free of bowel disease. Adenomatous polyps and tumor
samples were obtained from 5 patients, aged 53 to 75
during surgical resection. Samples were obtained after
informed consent and the study had been approved by the
local ethics committee (TUKEB 2005/037, Semmelweis
University Regional and Institutional Committee of Science
and Research Ethics, Budapest, Hungary). Tissue from core
tumor areas and normal tissue adjacent to tumor (NAT)
from two distances to the tumor were obtained: NAT1,
microscopically normal tissue from a distance of 1 cm from
tumor; and NAT2, minimum of 10 cm from tumor.
Surgically removed tissue samples were snap-frozen in
liquid nitrogen immediately after surgery and stored
at −80°C until cryosection.
Laser capture microdissection
Laser capture microdissection (LCM) was performed on
normal, adenomatous, and colorectal tumor mucosa
specimens after they were embedded in optimal cutting
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prepared for cryosectioning: 6 μm sections were cut on
PALM Membrane Slide 1.0 PEN (Carl Zeiss, Germany)
slides at −20°C and stored at −80°C until used. Consecutive
sections were used for H&E and IHC staining for LCM
and photo documentation. A PALM laser microdissector
(Carl Zeiss, Germany) was used to collect a total of 96
specimens with a target of approximately 1000 cells each,
as shown in Additional file 2: Table S2. Dissected specimens
were collected in 500 μl vials; specimens were immersed in
lysis buffer containing proteinase K immediately after sec-
tioning and kept at −80°C until further processing.
Preanalytic processing of LCM specimens
Microdissected samples were lysed at 56°C for three hours
followed by the addition of fresh proteinase K (ProtK) solu-
tion, and then overnight incubation at 37°C to ensure
complete digestion of the samples. All lysates were subjected
to bisulfite treatment without prior DNA extraction. To
further minimize DNA loss while maintaining high DNA
conversion rates a non-standard protocol was established.
Bisulfite reagents (from Epi proColon® 2.0 kit, Epigenomics,
Germany) were used with a modified protocol: 45 μl of
bisulfite solution plus 10 μl of protection buffer were
added to each lysate and incubated at 80°C for 45 minutes
in a thermocycler (MJ Research Tetrad, GMI, USA). Next,
binding buffer and poly-dA (Qiagen, Germany) were
added to the lysate solutions, which were then placed
on to silica membranes (Zymo Research, USA). On-
column desulfonation using 0.2 M NaOH for two minutes
was followed by two washing steps using commercial
buffer solutions AW1 and AW2 (Qiagen, Germany), and
finally, DNA was eluted using 40 μl of pre-warmed (50°C)
PCR-grade water. Eluted DNA was stored at −20°C until
used for analysis. The total amount of bisulfite-converted
DNA samples was quantified using an in-house duplex
qPCR assay which determines genomic and bisulfite DNA
simultaneously [23]. This assay determined the median
amount of DNA per specimen as 5.4 ng (Additional file 2:
Table S2) corresponding to a median of around 900 cells
per LCM specimen. 92% of the specimens had less than
1% detectable genomic DNA indicating a high conversion
of genomic DNA to bisulfite DNA. In two LCM samples,
unconverted genomic DNA comprised more than 10% of
the total DNA, indicating a poor conversion. However,
none of these samples were discarded as there was still a
sufficient amount of converted template DNA for the bi-
sulfite specific primers in the amplification and sequen-
cing assays. Multiplex PCR was then performed once per
sample using up to 2 ng of the respective DNA.
Sequencing assays and methylation analysis
To best utilize the limited amounts of DNA obtained from
microdissected specimens for the analysis of multiple loci, atwo-step multiplex amplification protocol was adopted [23]
to establish a 13-loci multiplex PCR (mPCR) (Additional
file 3: Table S3). For each locus at least two primer pairs
were designed and tested in singleplex PCR (sPCR) reac-
tions. The better performing primer pair, based on agarose
gel analysis, was then tested in combination with other
primers. All primers were void of CpGs so that amplifi-
cation was not influenced by the methylation status. PCR
was performed in two consecutive steps comprising a
pre-amplification (mPCR) on 2 ng bisulfite DNA from
each sample, and a re-amplification step for each of the
amplicons (sPCR). mPCR was done after initial de-
naturation for 15 minutes at 95°C for 50 cycles with
the following temperature profile: 20 seconds at 95°C,
45 seconds at 58°C, and 30 seconds at 72°C. The highly
stringent temperature was selected to minimize false
priming in the mPCR reaction, and high cycle numbers
were chosen to ensure sufficient amounts of PCR prod-
uct generated under these conditions. Re-amplification
of a single locus was done using the same forward pri-
mer as in the mPCR and a new reverse primer with a
short sequence tag (cgtcgtcg) at the 5′end, but other-
wise identical to the reverse primer of the mPCR. This
tag provided each amplicon with an internal calibrator
equivalent to three fully methylated CpGs. A volume of
2 μl of the mPCR product was used as the template of
each sPCR, and the same cycling conditions were used
for 45 cycles. All sample DNAs were subjected to one
mPCR pre-amplification reaction using a single 96-well
plate to minimize reaction to reaction variation. For
re-amplification with sPCR, we processed all sample-
specific mPCR products in parallel for each amplicon
to avoid batch processing effects.
Completed PCR reactions were subjected to direct
bisulfite sequencing using Sanger sequencing chemistry
as previously described [24]. Capillary gel analysis of
the purified products was performed on ABI 3730 XL
instruments by LGC Genomics (Berlin, Germany). Resulting
trace-file data were provided online and analyzed using
the ESME software to display methylation status as
heatmaps and numerically as previously described [25].
Numerical methylation values were obtained for each
CpG and averaged from all CpGs within each amplicon.
The resulting median was used to express methylation
levels as a percentage value for each amplicon and sam-
ple. Since all amplicons were reamplified and sequenced
only once per microdissected sample the obtained sequen-
cing data were then averaged as shown in Additional
file 2: Table S2 (number of biological replicates indicated
in last column).
Artificial mixtures of bisulfite-converted methylated
and unmethylated DNA were prepared to analyze the
technical performance of the assays in this workflow.
Bisulfite-converted fully methylated DNA from peripheral
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sperm DNA, previously reported to be free of methyla-
tion at most loci [23,26], were used to prepare mixtures
corresponding to 0%, 25%, 50%, 75%, and 100% methy-
lation. Quantification of the measured methylation level
was done after these known DNA standards and mix-
tures were processed in duplicate through all workflow
steps starting from pre-amplification to sequencing.
Statistical significance of methylation differences was
tested using one-way ANOVA analysis based on the quan-
titative sequencing data obtained for each amplicon.
IHC staining
Immunohistochemistry (IHC) staining was done as pre-
viously described [27] with modifications. Fresh-frozen
sections (6 μm) were fixed in acetone for 5 minutes and
air dried for 30 minutes. After fixation, the slides were
washed in PBS, followed by a 10-minute incubation in
1% BSA solution to block unspecific binding. Sections
were then incubated with the primary antibody against
Septin-9 (polyclonal AB cat.# PAB4799, Abnova, Germany)
in 1:50 dilution for 60 minutes at 37°C, washed again
in PBS, and detected with Alexa Fluor 546 dye in 1:100
dilution after 30 minutes of incubating at 37°C. Stain-
ing for cell nuclei was obtained with Hoechst 33258
(Sigma Aldrich, USA) dye for 10 seconds. The slides
were scanned using the Panoramic 250 FLASH scanner
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Results
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Figure 2 Amplicon calibration curves. Methylation of the artificial DNA mixtures is shown on the x-axis, and the experimentally determined
methylation value for each amplicon is shown on the y-axis. Both values are given as a percentage of fully methylated DNA.
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reproducible, even at lower levels of methylation, we
accepted these results in the absence of complete cali-
bration data. Together, these eight assays generated ro-
bust data from the 96 samples analyzed.
DNA methylation of SEPT9
The results obtained from the eight amplicons within
and near SEPT9 provided an overview of the methyla-
tion landscape of this gene for two different cell types
(Figure 3). One extragenic and three intragenic CpG
islands were designated as CGI1, CGI2, CGI3, and CGI4
(Figure 1). CGI3 was the largest of these CpG islands
and previously described as differentially methylated in
colorectal cancer [17]. This region was covered by three
non-overlapping amplicons to obtain a higher resolution
of methylation changes in the region.
Disease-associated aberrant methylation was seen ex-
clusively in CGI3 (Figure 3) while the other regions inSEPT9 did not show detectable alterations in their
methylation status. Amplicon 5, located centrally in CGI3,
showed large methylation differences between normal
samples and those from colon adenomas and tumors;
this difference was the most pronounced in epithelial
cells (Figures 3 and 4). The methylation difference be-
tween normal and tumor tissue in these cells exceeded
80% and was highly significant (p <0.0001). Equally pro-
nounced was the difference in epithelial cells between nor-
mal and adenomatous tissue. NAT1 samples (i.e., < 1 cm
from the tumor) showed significantly elevated methylation
levels (p <0.0001) in the epithelial cells in two of the
three tumors, a finding that supports the concept of a
field effect in CRC [28,29]. This effect was not seen in
the third NAT1 sample. No significant methylation dif-
ferences were observed between epithelial cells derived
from normal and NAT2 samples (p > 0.05). In contrast,
in stromal cells, an increase in methylation was seen
mainly in tumor samples with changes up to 50%, while
Figure 3 Bisulfite DNA sequencing results for SEPT9 amplicons. Each column displays results from one amplicon and each row displays
results for one cell type. Within each of the rectangular boxes, the columns correspond to single CpGs and the three rows correspond to three
patients. As all amplicons are drawn to the same scale the location of the amplicons is illustrated at the bottom with arrows pointing to the
genomic map (compare to Figure 1). Color coding: yellow = unmethylated (0%), green = partially methylated (50%), blue = fully methylated
(100%), and lighter or darker green/blue colors provide methylation levels below or above 50%. White areas = no sequencing data available.
Abbreviations: str = stromal cells, epi = epithelial cells, Norm = normal colon tissue, NAT1 = normal adjacent tissue (1 cm away from tumor),
NAT2 = normal adjacent tissue (> 10 cm from tumor), Adeno = adenoma tissue, pat = patient no.: only the last number of the patient ID in
Additional file 1: Table S1 is shown here.
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20%. No increase was detected in stromal cells of the
NAT samples. These data suggest that the observed ab-
errant methylation in SEPT9 - CGI3 originates in epi-
thelial cells and is associated with progression in the
adenoma-carcinoma sequence.
Our results further show spreading of aberrant methy-
lation from the core of CGI3 towards the 5′ end which
is covered by amplicon 4 (Figures 3 and 4). This methy-
lation expansion was seen only in tumor samples and
occurred in both epithelial and stromal cells. In aden-
oma samples the 5′end of CGI3 remained unmethylated.
The 3′ end of CGI3 (amplicon 6), and the region covered
by the neighboring amplicon 7 (located outside CGI3),
displayed elevated methylation in normal tissue samples
with epithelial cells showing higher methylation levels thanstromal cells (Figure 3). In amplicon 7, all epithelial samples
were fully methylated while stromal samples were partially
methylated. The tumor-associated increase in methylation,
which was seen with amplicon 5, was still detected with
amplicon 6 but did not affect the region covered by
amplicon 7. This pattern indicates the existence of a
DNA methylation boundary neighboring CGI3.
In addition to these major methylation patterns in
SEPT9, our results show patient-specific differences in
the level of methylation (Figure 3). These differences are
clearly seen in CGI3 but also seem to occur in CGI2
(amplicon 2). Although this study was based on a small
number of patients, the averaging of sequencing data from
several individual microdissected specimens (Additional
file 2: Table S2) provided a higher degree of robustness
against technical noise. Therefore, the subtle differences
Figure 4 Box plot diagrams of SEPT9 methylation. Results from amplicons 4 and 5 in different LCM tissue specimens. Data are shown separately for
stromal (str) and epithelial (epi) cells and for the three patients in each group. Red = epithelial cells, blue = stromal cells. The horizontal bar within boxes
shows the median, dots within the boxes the means, the lower and upper boundaries of boxes show the 25th and 75th percentiles, the whiskers are
determined by the 5th and 95th percentiles.
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especially when they appear in parallel in multiple
amplicons (e.g., amplicons 5 and 6). In most stromal
cells, amplicon 2 displayed higher methylation levels
(up to 25%) in comparison to epithelial cells in all five
tissue groups (Figure 3). Amplicon 2 is located within
CGI2, which is associated with the transcription start
site (TSS) of SEPT9_v1, the longest and possibly the
most prominent of the SEPT9 transcripts.
Immunohistochemistry
Antibody staining for Septin-9 was positive in all tissue
samples irrespective of disease status (Figure 5). In addition,
the protein was found in both epithelial and stromal cells,
although, at different levels. Septin-9 protein level was
significantly higher in epithelial cells than in stromal
cells derived from normal and NAT1 tissues (p <0.001)
(Figure 6). In adenoma and tumor samples, the epithe-
lial Septin-9 level was not different from that found in
stromal cells (Figure 6). In all five tissue groups, the
level of the Septin-9 protein in stromal cells was com-
parable with the lowest Septin-9 level found in tumor
samples.
Discussion
Methylation in SEPT9 CGI3
We investigated cell-type specific DNA methylation in
eight different regions of the SEPT9 gene in normal,
adenoma, and tumor tissues using LCM-separated pop-
ulations of epithelial and stromal cells. Our results showed
major changes in the methylation pattern in diseased tis-
sues in only one of the CpG islands investigated (CGI3).The observed aberrant methylation in adenoma and tumor
samples clearly originated in epithelial cells while in stromal
cells, hypermethylation at this locus occurred only after
hypermethylation in epithelial cells (Figure 3). The results
also indicate spreading of aberrant methylation from the
core of CGI3 to the 5′ end of the island. This methylation
expansion was observed only in CRC samples while in
adenoma samples, the 5′end of CGI3 remained clear of
methylation indicating that it is a relatively late event in
CRC formation. Such a distinctive methylation pattern
in the adenoma samples could be described as a transi-
tory methylation status which fits between the normal
and tumor samples. Together, these findings indicate that
methylation changes in the core of CGI3 of the SEPT9
gene reflect the cellular progression towards malignancy
in colon mucosa. These findings imply that alterations in
this differentially methylated region (DMR) within SEPT9
represent early events in colon carcinogenesis and may
directly contribute to colorectal tumor etiology. Although
stromal cells seemed to undergo molecular alterations
after changes to epithelial cells, the cells comprising the
stromal microenvironment are known to also play an
important role in the progression of cancer [30]. Epi-
genetic differences between epithelial and stromal cells
in colon cancer have already been explored in several
studies [31-33]. The exact mechanism by which the epi-
genetic status of one cell is transferred to a neighboring
cell is not understood, but it has been hypothesized
that multiple elements are involved, such as defects in
the epithelial basement membranes, composition of the
extracellular matrix, soluble agents (e.g., growth factors
and cytokines), and direct cell-to-cell contacts [34,35].
Figure 6 Quantification of immunohistochemistry results. Expression
of Septin-9 protein in stromal (blue boxes) and epithelial (red boxes) cells.
The Y axis displays arbitrary units for the normalized fluorescence
signals (ratio AlexaFluor 546 to Hoechst) in IHC slides. Each box plot
contains multiple scanned slide sections from three patients.
Figure 5 Histopathology and Septin-9 immunohistochemistry. The images for H&E staining and IHC were obtained from adjacent sections
and are from the same blocks used for LCM sampling. H&E staining in the left panel shows overall tissue morphology. The three IHC images per
patient are from one slide: Hoechst staining (blue) marks nuclei, AlexaFluor 546 (red) shows Septin-9 protein; the right panel shows the
combination of Hoechst and AlexaFluor 546. For better visualization of the Hoechst staining, these images were obtained with intensified
brightness for the blue channel. Normal sections are from BSM0451; NAT1, NAT2, and tumor are from BSM0456, and adenoma is from BSM0457.
All images are at 20x magnifications; the scale bars correspond to 100 μm.
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acquire the potential for proteolytic degradation of the
basement membrane and actively migrate into the sur-
rounding mesenchymal compartment, which requires the
dissolution of intracellular and cell-matrix contacts [34].
Because Septin-9 is involved in cytokinesis, it is possible
that a deregulated SEPT9 gene could impact the pro-
pensity of a cell for migration and invasiveness. Add-
itionally, accumulating evidence describing the involvement
of SEPT9 in the mechanism of epithelial-mesenchymal
transition [36] provides further support for such a con-
nection. Considering that transcription of SEPT9 produces
several different isoforms, a particular ratio of these
transcripts may be needed to sustain normal cellular
physiology. If disease-related hypermethylation, such as
what we observed with CGI3, suppresses the normal ex-
pression of one of these transcripts, differently structured
filaments may form affecting key cellular functions [8].
Both the genomic location of CGI3 and the presence of
a TSS in this specific region (Figure 1) strongly suggest
a direct role in the regulation of transcript variant 2 (tv-2).
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the expression of this or any of the other transcripts is
altered in epithelial cells in adenoma and in colorectal
cancer. It is of further interest to note that CGI3 also
harbors the specific CpGs interrogated by the early CRC
detection test, Epi proColon®, which is currently available
for clinical application in Europe [21]. Our findings pro-
vide further evidence that Epi proColon® targets SEPT9 at
the most informative site of this biomarker gene.
Immunohistochemistry
Our results from the IHC analysis of the different tissues
indicated a significant reduction of epithelial Septin-9
protein levels in adenoma and tumor tissue. It is tempt-
ing to speculate that the increase in SEPT9 methylation
of CGI3 in adenoma and tumor samples is directly re-
sponsible for the reduced Septin-9 expression levels.
However, our current methylation data alone cannot ex-
plain the different levels of Septin-9 protein in epithelial
and stromal cells, as stromal cells display low levels of
Septin-9 protein and their SEPT9 gene is not methylated.
Additionally, the increased SEPT9 methylation seen in
NAT1 samples and in stromal cells of tumor tissue does
not seem to be reflected in a corresponding reduction
in protein levels in the same samples. Nevertheless, it is
interesting that a reduction of Septin-9 protein levels in
epithelial cells was also found in an earlier exploratory
study in which a different antibody for Septin-9 detec-
tion was used [27]. In our present study, the polyclonal
antibody targeted a sequence of 29 amino acids close to
the C-terminal end, which is preserved in at least seven
Septin-9 isoforms. The antibody used in the previous
study targeted a region with a variable length close to
the N-terminus detecting only three Septin-9 isoforms.
Despite these differences, both studies provided evidence
for a reduced Septin-9 protein level in colon adenoma and
in CRC. Each of the Septin-9 proteins will need to be
targeted simultaneously with highly specific monoclonal
antibodies to determine whether the observed aberrant
methylation in one CpG island leads to a reduction in pro-
tein expression, and if all isoforms are affected equally.
Furthermore, histone modifications within SEPT9 may
need to be considered in different cell types as these
modifications are known to impact the regulation of
transcription [37].
Methylation in additional SEPT9 regions
While CGI3 is a DMR in cells of the colon mucosa, the
same cannot be said for other regions analyzed in this
study. Earlier studies reported evidence for epigenetic
regulation of SEPT9 in ovarian cancer [38] and in head
and neck cancer [39], but did not indicate the exact
regions involved. Epigenetic regulation of SEPT9 was
recently implicated in breast cancer by Connolly et al.[16] who reported increased total SEPT9 mRNA expres-
sion and an overall increase in Septin-9 protein levels in
breast cancer tissue when compared with normal tissue.
In addition, the group found the silencing of a specific
transcript variant 3 (tv-3) and the decrease of the Septin-9
protein encoded by tv-3. Elevated methylation in tumor
and NAT tissue samples was proposed to trigger these
effects. However, the reported region is CpG poor when
mapped to the current hg19 build of the human genome,
upstream of the first exon for tv-3. The same region is
located about 3 kb upstream of amplicon 3 in our study
(Figure 1). The reported absolute methylation levels be-
tween normal and tumor tissues differed by less than
12%. In comparison, differential methylation in the core
of CGI3 seen in our study exceeded 80% in epithelial
cells. It remains to be demonstrated whether the same
CpG islands in SEPT9 are aberrantly methylated in dif-
ferent tumors and how those CpG islands may impact
the expression of the various mRNAs.
Methylation boundary
The consistently methylated region covered by amplicon
7, positioned approximately 2 kb downstream of CGI3,
stood out as a characteristic feature in the SEPT9 methy-
lation landscape of our samples (Figure 3). We compared
our results with publicly available next-generation se-
quencing data [40]. This database also indicated complete
methylation in this particular region in all cell types for
which data were available. In addition, the presence of a
CTCF binding site approximately 100 bp downstream of
amplicon 6 further underscores the functional relevance
of this region [41]. Supported by these observations, we
concluded that the region around amplicon 7 represents
a DNA methylation boundary. Stromal cells in this re-
gion consistently displayed lower levels of methylation,
which further supports our observation of epigenetic
differences between stromal and epithelial cell types.
Boundary elements are frequent features of CpG islands,
and they define functionally important domains, such as
insulators that may block enhancer activities [42]. The
boundary elements, however, are not unchangeable fea-
tures of a particular region. Loss of methylation bound-
aries have been described in fragile-X syndrome [43],
and the shift of boundary elements, either inward or
outward of the respective CGI, were reported in colon
cancer [44]. Either of these situations leads to a loss of
methylation stability in the DMR. Interestingly, while
our data indicate the presence of a methylation bound-
ary downstream of CGI3, it seems that the position is
not shifted in tumor tissue and does not disappear as
the location of this element in the region of amplicons 6
and 7 persists in both adenoma and tumor tissues. Genome-
wide methylation analyses of the colon have suggested that
local detection of CGI hypermethylation usually reflects
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ies will be required to determine whether this model also
applies to SEPT9 or if this CGI is unusual, e.g., it is flanked
by a position invariable methylation boundary.
Conclusions
Our results support the idea that epigenetic deregulation
of SEPT9 plays a role in the development of colorectal
cancer. Aberrant hypermethylation of this gene occurs
only in one of its CpG islands and this hypermethylation
likely is an early event in the adenoma-carcinoma sequence.
Tumor-associated aberrant methylation in the colon mu-
cosa originates in epithelial cells and precedes similar alter-
ations in stromal cells. Our data further provide a direct
link between the region interrogated by the Epi proColon®
assay, which detects methylation of SEPT9 in cell-free DNA
in plasma and the underlying events in the tissue of cancer
patients. It is now evident that the Epi proColon® test, cur-
rently available for clinical application in Europe, obtains
its diagnostic utility by targeting the very region of the
SEPT9 promoter that displays the highest susceptibility
to methylation changes in the adenoma-carcinoma se-
quence. Additional applications of this biomarker in
oncology, beyond the known utility for diagnostic screen-
ing, are also conceivable.
Endnotes
aThroughout this manuscript the human gene septin 9
is described with the gene symbol name “SEPT9” while
“Septin-9” is used for the protein, following the recommended
nomenclature by Expasy Gene/Protein Synonyms databank
and UniProt database.
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